1. Profound Medical closed a registered direct offering of 5.1 million shares. 2. The offering raised approximately $36 million for corporate expansion. 3. Funds will support marketing, R&D, and strategic transactions. 4. A private placement for Canadian investors is set to close soon. 5. The TULSA-PRO system enhances non-invasive prostate treatment capabilities.
FAQ
Why Bullish?
The substantial capital influx suggests business growth potential, enhancing investor confidence. Historical precedents for companies raising funds to improve operations typically lead to price increases.
How important is it?
The capital raised and intended uses are directly relevant to Profound's growth trajectory and market strategy, potentially influencing future revenue.
Why Long Term?
Utilization of funds for R&D and marketing is expected to enhance product visibility and market penetration over time, similar to growth seen in tech-driven healthcare companies post-financing.
Profound Medical Corp. Completes $36 Million Registered Direct Offering
Profound Medical Corp. (NASDAQ: PROF; TSX: PRN), a leader in AI-powered medical solutions, has successfully closed its registered direct offering of 5,142,870 common shares at a price of $7.00 per share. This offering has generated approximately $36 million in gross proceeds, which will be utilized to enhance various operational areas of the company.
Details of the Offering
The equity investment, structured without warrant coverage, was primarily supported by healthcare-focused investors, alongside existing shareholders. The Company is set to deploy the net proceeds from the offering for:
- Expansion of sales and marketing efforts
- Working capital and general corporate purposes
- Research and development initiatives
- Strategic transactions
Konik Capital Partners, LLC, a division of T.R. Winston and Company, acted as the exclusive placement agent. This registered offering was conducted under an effective shelf registration statement on Form S-3, which was approved by the SEC on December 4, 2025.
Upcoming Private Placement
In addition to this offering, Profound Medical Corp. plans to undertake a private placement aimed at certain Canadian purchasers. The closure of this private placement is anticipated on or before December 30, 2025, contingent upon acquiring all necessary approvals, including conditional approval from the Toronto Stock Exchange. It is noteworthy that no securities will be sold to U.S. purchasers.
About Profound Medical Corp.
Profound Medical Corp. specializes in developing innovative, AI-driven medical technologies that facilitate incision-free therapies for tissue ablation. Its flagship product, the TULSA-PRO®, integrates real-time MRI capabilities with AI-enhanced treatment planning and robotically-driven ultrasound.
The TULSA Procedure™ demonstrates promising results across various prostate disease profiles, from low to high-risk prostate cancer and benign prostatic hyperplasia (BPH). This procedure is designed to ensure patient safety and comfort, facilitating a quick recovery without the need for hospitalization.
Additionally, Profound's Sonalleve® platform is recognized for treating uterine fibroids and other medical conditions, further highlighting the company’s commitment to advancing non-invasive treatments.
Forward-Looking Statements
This announcement contains forward-looking statements relating to the Company and its anticipated business plans. Such statements may involve risks and uncertainties which could lead to actual results differing from those expected. Readers are encouraged to review Profound's filings with U.S. and Canadian securities regulators to understand the risks involved.